A drug developed to treat chronic obstructive pulmonary disease in humans can be the answer to treating spinal cord injuries. The drug, known as AZD1236, has shown impressive results on mice suffering from spinal cord injuries and researchers from the University of Birmingham believe that they will be testing it on humans very soon. Spinal injuries are quite common in the United Kingdom and if the testing is successful, the drug can also be used to treat conditions such as osteoarthritis.

Also read |&nbsp;<a href="https://www.wionews.com/world/part-of-skull-dating-back-almost-8000-years-found-in-minnesota-river-480767" hreflang="en">Part of skull dating back almost 8,000 years found in Minnesota River</a>

The results of the study, published in the journal Clinical and Translational Medicine, state that the mice showed almost 80-85 per cent improvement after the drug was administered. The results were also found to be quite similar whether the drug is given 24 hours or six weeks after the injury.

The report explained the drug blocks the action of enzymes - MMP-9 and MMP-12 – which cause swelling after suffering a spinal cord injury and lowers the inflammation and pain in the area.

“What we’re doing is we’re dampening down the damage to the nerve tissues. That way, we’re preserving more and more of the neurons,” said Prof Zubair Ahmed according to The Guardian.

Also read |&nbsp;<a href="https://www.wionews.com/world/nasa-has-identified-something-weird-happening-to-the-universe-480678" hreflang="en">NASA has identified 'something weird' happening to the universe</a>

With the experiments on mice showing good results, the next move will be to test the medicine on humans. According to The Guardian, around 2500 people suffer spinal cord injuries in the United Kingdom every year and this can be the answer to a problem that was deemed irreversible till now.

“Five to six years and this could be a potential treatment, if everything goes well,” he said.

WATCH WION LIVE HERE -

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

A drug developed to treat chronic obstructive pulmonary disease in humans can be the answer to treating spinal cord injuries. The drug, known as AZD1236, has shown impressive results on mice suffering from spinal cord injuries and researchers from the University of Birmingham believe that they will be testing it on humans very soon.

A drug developed to treat chronic obstructive pulmonary disease in humans can be the answer to treating spinal cord injuries. The drug, known as AZD1236, has shown impressive results on mice suffering from spinal cord injuries and researchers from the University of Birmingham believe that they will be testing it on humans very soon. Spinal injuries are quite common in the United Kingdom and if the testing is successful, the drug can also be used to treat conditions such as osteoarthritis. Also read | Part of skull dating back almost 8,000 years found in Minnesota River The results of the study, published in the journal Clinical and Translational Medicine, state that the mice showed almost 80-85 per cent improvement after the drug was administered. The results were also found to be quite similar whether the drug is given 24 hours or six weeks after the injury. The report explained the drug blocks the action of enzymes - MMP-9 and MMP-12 – which cause swelling after suffering a spinal cord injury and lowers the inflammation and pain in the area. “What we’re doing is we’re dampening down the damage to the nerve tissues. That way, we’re preserving more and more of the neurons,” said Prof Zubair Ahmed according to The Guardian. Also read | NASA has identified 'something weird' happening to the universe With the experiments on mice showing good results, the next move will be to test the medicine on humans. According to The Guardian, around 2500 people suffer spinal cord injuries in the United Kingdom every year and this can be the answer to a problem that was deemed irreversible till now. “Five to six years and this could be a potential treatment, if everything goes well,” he said. WATCH WION LIVE HERE -

Drug developed for lung diseases shows great results in mice with spinal cord injuries

The&nbsp;European&nbsp;Union’s&nbsp;(EU) drug watchdog is looking to warn general public about a ‘very rare’ possibility of leading to spinal cord inflammation after getting vaccinated with coronavirus vaccines manufactured by AstraZeneca and Johnson &amp; Johnson.&nbsp;

For this, the European Medicines Agency is also considering to place warning labels on these Covid jabs. &nbsp;

It also said that there was a “reasonable possibility” that they may have resulted in a spinal inflammation on rare occasions. &nbsp;

Also Read:&nbsp;<a href="https://www.wionews.com/world/covid-pandemic-benefit-face-masks-help-people-look-good-says-uk-study-444609" hreflang="en">Covid pandemic benefit? Face masks help people look good, says UK study</a>

On Friday, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) after holding three days of meetings and discussions said that it wants to include a warning for “very rare cases of transverse myelitis (TM) reported following vaccination” with Vaxzevria and Janssen jabs. &nbsp;&nbsp;

The panel also added that the condition was an “adverse reaction of unknown frequency” to the vaccine profile. &nbsp;

It comes as PRAC reviewed information on reported cases in the world and scientific literature. &nbsp;&nbsp;

Also Read:&nbsp;<a href="https://www.wionews.com/world/unvaccinated-women-with-covid-are-more-likely-to-lose-fetuses-and-infants-scottish-data-shows-444707" hreflang="en">Unvaccinated women with Covid are more likely to lose fetuses and infants, Scottish data shows</a>

According to the EMA, TM is a rare neurological condition, which is characterised by an “inflammation of one or both sides of the spinal cord.” It can cause weakness in arms or legs, numbness, tingling, pain or loss of pain sensation and problems with bowel and bladder function. &nbsp;

It concluded that “a causal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility.” However, it said the “benefit-risk profile of both vaccines remains unchanged.” &nbsp;&nbsp;

(With inputs from agencies)&nbsp;

The European Union’s (EU) drug watchdog is looking to warn general public about a ‘very rare’ possibility of leading to spinal cord inflammation after getting vaccinated with coronavirus vaccines manufactured by AstraZeneca and Johnson & Johnson.

The European Union’s (EU) drug watchdog is looking to warn general public about a ‘very rare’ possibility of leading to spinal cord inflammation after getting vaccinated with coronavirus vaccines manufactured by AstraZeneca and Johnson & Johnson. For this, the European Medicines Agency is also considering to place warning labels on these Covid jabs. It also said that there was a “reasonable possibility” that they may have resulted in a spinal inflammation on rare occasions. Also Read: Covid pandemic benefit? Face masks help people look good, says UK study On Friday, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) after holding three days of meetings and discussions said that it wants to include a warning for “very rare cases of transverse myelitis (TM) reported following vaccination” with Vaxzevria and Janssen jabs. The panel also added that the condition was an “adverse reaction of unknown frequency” to the vaccine profile. It comes as PRAC reviewed information on reported cases in the world and scientific literature. Also Read: Unvaccinated women with Covid are more likely to lose fetuses and infants, Scottish data shows According to the EMA, TM is a rare neurological condition, which is characterised by an “inflammation of one or both sides of the spinal cord.” It can cause weakness in arms or legs, numbness, tingling, pain or loss of pain sensation and problems with bowel and bladder function. It concluded that “a causal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility.” However, it said the “benefit-risk profile of both vaccines remains unchanged.” (With inputs from agencies)

Covid jabs may lead to ‘very rare’ spinal cord inflammation, says EU’s drug watchdog

spinal-cord-inflammation

Spinal Cord Inflammation, News on Spinal Cord Inflammation, stories on Spinal Cord Inflammation, articles on Spinal Cord Inflammation, Spinal Cord Inflammation stories at Wion, Spinal Cord Inflammation news, Spinal Cord Inflammation latest news

spinal cord-inflammation

Drug developed for lung diseases shows great results in mice with spinal cord injuries

Covid jabs may lead to ‘very rare’ spinal cord inflammation, says EU’s drug watchdog